MADRIGAL PHARMACEUTICALS INC (MDGL)
US5588681057 - Common Stock
MDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024
MDGL stock results show that Madrigal Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis...
Madrigal Statement on the Passing of Dr. Stephen Harrison
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We...
Madrigal Pharmaceuticals Becomes Oversold (MDGL)
6 Stocks Positioned to Soar as Investors Focus on MASH
Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was expanded to treat obesity, an even bigger market. JP Morgan analyst Richard Vosser estimated the global obesity drug market will reach $71 billion by 2032.
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel...
7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024
Analyst-backed stocks have a high correlation with future stock price growth. Here are seven stocks with a high number of recent upgrades.
2 Under-the-Radar Growth Stocks to Consider
Don't ignore these innovative companies.
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
These businesses should see good times ahead.
Commit To Buy Madrigal Pharmaceuticals At $170, Earn 11.6% Annualized Using Options
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing...
1 No-Brainer Growth Stock to Buy Now
This liver-disease specialist might be significantly undervalued.
The 3 Best Biotech Stocks to Buy in April 2024
Biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April.
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
Both stocks are pretty risky, but one of them more so than the other.
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
This biotech just got clearance to dive into a deep ocean of a market.
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
The mid-cap biotech has succeeded where many others failed.
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Madrigal has one key advantage over its two huge potential future rivals.
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering...
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Madrigal Pharmaceuticals Announces Proposed Public Offering
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering...
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Why Is Geron (GERN) Stock Up 94% Today?
Geron stock is on the rise Friday with heavy trading of GERN shares after the company's blood disorder drug got new backing.
MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today
Madrigal Pharmaceuticals stock is up on Friday as MDGL investors celebrate FDA approval of NASH treatment Rezdiffra today.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning!
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”)Accelerated approval was based on Phase...
First Drug to Treat Common, Lethal Liver Disease Gets US Nod
Madrigal Pharmaceuticals Inc.’s drug Rezdiffra gained the first US approval to treat a potentially deadly liver disease that affects millions worldwide, succeeding in an area where some bigger rivals have failed.